Prevalence of deep vein thrombosis (DVT) in non-surgical patients at hospital admission

Thrombosis and Haemostasis

Volumn 98, Issue 4, 2007, Pages 765-770

  Lawall, Holger ^a   Hoffmanns, Wibke ^a   Hoffmanns, Phillip ^a   Rapp, Uli ^a   Ames, Michael ^a   Pira, Alessandro ^a   Paar, W Dieter ^b   Bramlage, Peter ^c   Diehm, Curt ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Deep venous thrombosis; Medical patients; Prevalence; Ultrasonography; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; D DIMER; FIBRINOGEN; HEPARIN; PHENPROCOUMON;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; DEATH; DEEP VEIN THROMBOSIS; FEMALE; FEMORAL VEIN; HEART DEATH; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POPLITEAL VEIN; PREVALENCE; PRIORITY JOURNAL; RELAPSE; SEPSIS; SURGICAL PATIENT; SURVIVAL;

AGED; C-REACTIVE PROTEIN; DIMERIZATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 35048825241     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-02-0107     Document Type: Article

References (32)

1. Heit JA, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
2. Nicolaides AN, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37.
3. Geerts WH, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
4. Bramlage P, et al. Current concepts for the prevention of venous thromboembolism. Eur J Clin Invest 2005; 35 (Suppl 1): 4-11.
5. Cunningham RS. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis. Semin Oncol 2006; 33: S17-25; quiz S41-42.
6. Samama MM, et al. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 2003; 88: 1410-1421.
7. Howell MD, et al. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001; 54: 810-816.
8. Alikhan R, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968.
9. Samama MM, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
10. Leizorovicz A, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
11. Cohen AT, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006; 332: 325-329.
12. Emerson PA, Marks P. Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. Br Med J 1977; 1: 18-20.
13. Handley AJ. Low-dose heparin after myocardial infarction. Lancet 1972; 2: 623-624.
14. Nicolaides AN, et al. Myocardial infarction and deep-vein thrombosis. Br Med J 1971; 1: 432-434.
15. Warlow C, et al. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973; 2: 934-936.
16. Belch JJ, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 115-117.
17. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-450.
18. Dahan R, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 159-164.
19. Oger E, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002; 88: 592-597.
20. Hull RD, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 2006; 22: 31-38.
21. Haas S, Haas P. Low molecular weight heparins - their application in clinic and practice. 1999, Steinen: Zett Verlag, ISBN 3926770139.
22. Prescott SM, et al. Venous thromboembolism in decompensated chronic obstructive pulmonary disease. A prospective study. Am Rev Respir Dis 1981; 123:32-36.
23. Schonhofer B, Kohler D. Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease. Respiration 1998; 65: 173-177.
24. Anderson FA, Jr., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.
25. Couturaud F, et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 2006; 96: 744-749.
26. Jimenez D, et al. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost 2006; 95: 562-566.
27. Schulman S, Ogren M. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost 2006; 96: 258-266.
28. Dunn AS, et al. The magnitude of an iatrogenic disorder: a systematic review of the incidence of venous thromboembolism for general medical impatients. Thromb Haemost 2006; 95: 758-762.
29. Samana MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
30. Bucek RA, et al. C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol 2002; 119: 385-389.
31. Rumley A, et al. Effects of older age on fibrin D-dimer, C-rcactive protein, and other hemostatic and inflammatory variables in men aged 60-79 years. J Tromb Haemost 2006; 4: 982-987.
32. Bressollette L, et al. Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients-the TADEUS project. Thromb Haemost 2001; 86: 529-533.